Clinical Trial Update: A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating pharmacokinetics, safety, and efficacy of solifenacin for neurogenic detrusor overactivity in children aged 6 months to under…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity

Drugs mentioned

• Solifenacin (solifenacin)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Neurogenic Detrusor Overactivity, Pediatric | Phase 3 | Status: COMPLETED | Results posted: 2018-06-21